Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Paraneoplastic Syndromes Involving the Nervous System
NEJM 349:1543-1554, Darnell,R.B. &Posner,J.B., 2003
Thymoma in Patients with MG
Neurol 59:1844-1850, Evoli,A.,et al, 2002
Paraneoplastic Syndromes
Arch Neurol 56:405-408, Dalmau,J.O.&Posner,J.B., 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Calcium Channels in Neurological Disease
Ann Neurol 42:275-282, Greenberg,D.A., 1997
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Paraneoplastic Cerebellar Degener III, Cerebellar Degener, Cancer & Lambert-Eaton Myasthenic Synd
Neurol 42:1944-1950, Clouston,P.D.,et al, 1992
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
The Remote Effects of Cancer on the Nervous System
in Neurol Manif of Systemic Dis, W. B. Saunders, Co, Phila, Neurologic Clinics 7:579-603, Dropcho,E.J., 1989
The Lambert-Eaton Myasthenic Syndrome, A Review of 50 Cases
Brain 111, 577-5961988., O'Neill,J.H.,et al, 1988
The Neurotoxicity of Antibacterial Agents
Ann Int Med 101:92-104, Snavely,S.R.,et al, 1984
Myasthenia Gravis & Myasthenic Syndromes
Ann Neurol 16:519-534, Engel,A.G., 1984
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Clinical Manifestations of Myasthenia Gravis
UptoDate Aug 2016, Bird, S.J., 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Myasthenia in Pregnancy: Best Practice Guidelines from a UK Multispecialty Working Group
JNNP 85:538-543, Norwood, F.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
The Neurologist 12:231-239, Kusner,L.,et al, 2006
Does This Patient Have Myasthenia Gravis?
JAMA 293:1906-1914, Scherer,K.,et al, 2005
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Steroid Treatment for Myasthenia Gravis
Muscle Nerve 25:115-121, Rivner,M.H., 2002
A Practical Approach to the Diagnosis and Management of MELAS: Case Report and Review
The Neurologist 8:302-312, Thambisetty,M.,et al, 2002
The Expanding Spectrum of Herpesvirus Infections of the Nervous System
Brain Pathology 11:440-451, Kleinschmidt-DeMasters,B.K. &Gilden,D.H., 2001
Vertical Diplopia
Semin Neurol 20:21-30, Acierno,M.D., 2000
Practice Parameter: Thymectomy for Autoimmune Myasthenia Gravis (an Evidence-based Review)
Neurol 55:7-15,3, Gronseth,G.S. & Barohn,R.J., 2000
Distal Myasthenic Gravis
Neurol 52:632-634, Nations,S.P.,et al, 1999
Respiratory Management in Acute Neurologic Illness
Neurol 50:11-20, Wijdicks,E.F.M.&Borel,C.O., 1998
Binocular Vertical Diplopia
Mayo Clin Proc 73:55-66, Brazis,P.W.&Lee,A.G., 1998
Thymectomy for Myasthenia Gravis
Neurol 48 (Suppl 5) :S52-S63997., Jaretzki,A., 1997
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
Myasthenic Crisis:Clinical Features, Mortality, Comp, & Risk Factors for Prolonged Intubation
Neurol 48:1253-1254, Thomas,C.E.,et al, 1997